BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28893623)

  • 1. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
    Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
    Fehl C; Vogt CD; Yadav R; Li K; Scott EE; Aubé J
    J Med Chem; 2018 Jun; 61(11):4946-4960. PubMed ID: 29792703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of the inhibiting impact of abiraterone D4A metabolite on human steroid 21-monooxygenase (CYP21A2).
    Masamrekh R; Filippova T; Haurychenka Y; Shcherbakov K; Veselovsky A; Strushkevich N; Shkel T; Gilep A; Usanov S; Shumyantseva V; Kuzikov A
    Steroids; 2020 Feb; 154():108528. PubMed ID: 31678135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
    Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
    Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.
    Dhir V; Ivison HE; Krone N; Shackleton CH; Doherty AJ; Stewart PM; Arlt W
    Mol Endocrinol; 2007 Aug; 21(8):1958-68. PubMed ID: 17505056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
    de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
    J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer.
    Kosaka T; Miyajima A; Yasumizu Y; Miyazaki Y; Kikuchi E; Oya M
    Steroids; 2014 Dec; 92():39-44. PubMed ID: 25150014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
    Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
    J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
    Bordeau BM; Ciulla DA; Callahan BP
    ChemMedChem; 2016 Sep; 11(18):1983-6. PubMed ID: 27435344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM; Abbott DH
    J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
    Cheong EJY; Nair PC; Neo RWY; Tu HT; Lin F; Chiong E; Esuvaranathan K; Fan H; Szmulewitz RZ; Peer CJ; Figg WD; Chai CLL; Miners JO; Chan ECY
    J Pharmacol Exp Ther; 2020 Sep; 374(3):438-451. PubMed ID: 32554434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
    Petrunak EM; Bart AG; Peng HM; Auchus RJ; Scott EE
    J Biol Chem; 2023 Mar; 299(3):102999. PubMed ID: 36773804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the unique benzodiazepine structure interacting with CYP enzymes to affect steroid synthesis in vitro?
    Johannsen ML; Munkboel CH; Jørgensen FS; Styrishave B
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105765. PubMed ID: 32991989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
    Brossard D; Zhang Y; Haider SM; Sgobba M; Khalid M; Legay R; Duterque-Coquillaud M; Galera P; Rault S; Dallemagne P; Moslemi S; El Kihel L
    Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPR-Based study of affinity of cytochrome P450s / redox partners interactions modulated by steroidal substrates.
    Ershov PV; Yablokov ЕO; Florinskaya AV; Mezentsev YV; Kaluzhskiy LА; Tumilovich AM; Gilep АА; Usanov SA; Ivanov АS
    J Steroid Biochem Mol Biol; 2019 Mar; 187():124-129. PubMed ID: 30468857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
    DeVore NM; Scott EE
    Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minor activities and transition state properties of the human steroid hydroxylases cytochromes P450c17 and P450c21, from reactions observed with deuterium-labeled substrates.
    Yoshimoto FK; Zhou Y; Peng HM; Stidd D; Yoshimoto JA; Sharma KK; Matthew S; Auchus RJ
    Biochemistry; 2012 Sep; 51(36):7064-77. PubMed ID: 22873692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoxidation activities of human cytochromes P450c17 and P450c21.
    Yoshimoto FK; Peng HM; Zhang H; Anderson SM; Auchus RJ
    Biochemistry; 2014 Dec; 53(48):7531-40. PubMed ID: 25386927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
    Song D; Zhang J; Wang Y; Hu J; Xu S; Xu Y; Shen H; Wen X; Sun Z
    J Biomol Struct Dyn; 2019 Oct; 37(16):4161-4170. PubMed ID: 30431391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.